



© Musée des arts et métiers/J.-M. Courant/Dephti Ouest

PARIS PSVD MEETING

DECEMBER 04TH AND 05TH



Organizing committee
Laure Elkrief,
Virginia Hernandez-Gea,
Pierre-Emmanuel Rautou

*Conservatoire National des Arts et Métiers (CNAM)
292 rue Saint Martin, 75003 Paris*

Day 1: COST EURO-VALDI-NET meeting PSVD

Current knowledge and future directions for PSVD

8H30
-
8H50 | *Welcome of participants*

8H50
-
9H00 | *Opening and introductory words*

9H00
-
11H00 | *Session 1: Pathophysiology
and conditions associated with PSVD*

1/ Conditions associated with PSVD; impact on prognosis and impact of their treatment on PSVD

2/ Genetics and PSVD

3/ Pathophysiology: is PSVD an immune, a vascular or a coagulation disorder?

4/ Preclinical models of PSVD

11H00
-
11H30 | *Coffee Break*

11H30
-
12H50

Session 2: Diagnosis and Natural history of PSVD

1/ When should PSVD be suspected?

2/ PSVD without portal hypertension

3/ Prognostic and natural history of PSVD with signs of portal hypertension

12H50
-
14H00

Lunch Break

14H00
-
15H00

Session 3: Diagnostic tools in PSVD

1/ Imaging and PSVD: how to improve diagnosis and prognostic?

2/ Pathological changes in PSVD: current view and future directions

15H00
- **Session 4: Challenges in PSVD**
16H10

1/ Can PSVD regress?

2/ Can PSVD lead to cirrhosis?

3/ Nodules in PSVD

16H10
- **Coffee Break**
16H40

16H40
- **Session 5: Management of PSVD**
18H40

1/ Hemodynamic changes in PSVD and their modulation

2/ Management of complications of portal hypertension in PSVD: should that really be the same as in cirrhosis?

3/ Liver transplantation in PSVD

4/ Specificities of PSVD in children and transition to adulthood

18H30 **Concluding remarks**

Day 2: FILFOIE-ERN PSVD meeting

Consensus statement on clinical trials in PSVD

09H00

-

11H00

Session 1: Break out session on clinical trials in PSVD

1/ Inclusion criteria for studies on PSVD

2/ Surrogate markers of outcome in PSVD: does and don't

3/ Hard endpoints in PSVD studies

11H00

-

11H30

Coffee Break

11H30

-

12H30

Session 2: Innovations for clinical trials in PSVD

1/ Innovative trial design for rare diseases

2/ HRQOL and PRO in patients with PSVD

12H30

-

13H30

Lunch Break

13H30
-
15H30

Session 3

1/ *Novel therapies and therapeutic approaches*

2/ *Feed-back from the working groups*

a/ *Inclusion criteria for studies on PSVD*

b/ *Surrogate markers of outcome in PSVD: does and don't*

c/ *Hard endpoints in PSVD studies*

15H30
-
16H00

Wrap-Up

Thanks to our scientific partners



MALADIES RARES DU FOIE
DE L'ADULTE ET DE L'ENFANT

FILIÈRE DE SANTÉ

